Reaction
Hormone Receptor Positive Her2 Negative Breast Cancer reporting signals
As of the last recalculation, Hormone Receptor Positive Her2 Negative Breast Cancer appears in 310 FAERS reports alongside 11 co-occurring drug terms. The strongest observed disproportionality signal is RIBOCICLIB (PRR 1,147.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ribociclib | 197 | 1,147.9 | 1,155.2 |
| Fulvestrant | 126 | 430.8 | 432.4 |
| Letrozole Tablets | 134 | 328.7 | 329.6 |
| Letrozole | 153 | 328.4 | 329.2 |
| Alpelisib | 21 | 173.4 | 173.9 |
| Goserelin | 13 | 67.8 | 67.9 |
| Abemaciclib | 18 | 64.1 | 64.2 |
| Zoledronic Acid | 30 | 55.4 | 55.5 |
| Exemestane | 16 | 52.8 | 52.9 |
| Everolimus Tablets | 12 | 49.9 | 50.0 |
| Palbociclib | 42 | 34.0 | 34.1 |